CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,812,468
- in 11 filings, $79.8M under 10b5-1 plans
Net −$79,812,468. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-03 | Inrig Jula CHIEF MEDICAL OFFICER | Sale 10b5-1 | −2,066 | $19.10 | $39K | 59,883 |
| 2024-12-26 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 | +15,000 | $12.67 | $190K | 69,927 |
| 2024-12-26 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −15,000 | $17.22 | $258K | 54,927 |
| 2024-12-26 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −15,000 | 0 | ||
| 2024-11-25 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise | +15,000 | $12.67 | $190K | 67,017 |
| 2024-11-25 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Sale | −12,090 | $18.30 | $221K | 54,927 |
| 2024-11-25 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise · Employee stock option (right to buy) | −15,000 | 15,000 | ||
| 2024-10-04 | LYONS GARY A Director | Option exercise 10b5-1 | +40,000 | $10.48 | $419K | 91,000 |
| 2024-10-04 | LYONS GARY A Director | Sale 10b5-1 | −21,179 | $14.35 | $304K | 69,821 |
| 2024-10-04 | LYONS GARY A Director | Sale 10b5-1 | −18,821 | $15.15 | $285K | 51,000 |
| 2024-10-04 | LYONS GARY A Director | Option exercise · Stock option (right to buy) 10b5-1 | +40,000 | 0 | ||
| 2024-09-30 | Meckler Jeffrey A Director | Option exercise 10b5-1 | +40,000 | $10.48 | $419K | 121,000 |
| 2024-09-30 | Meckler Jeffrey A Director | Sale 10b5-1 | −40,000 | $14.06 | $562K | 81,000 |
| 2024-09-30 | Meckler Jeffrey A Director | Option exercise · Stock option (right to buy) 10b5-1 | +40,000 | 0 | ||
| 2024-09-10 | Inrig Jula CHIEF MEDICAL OFFICER | Sale 10b5-1 | −684 | $12.98 | $9K | 61,949 |
| 2024-09-09 | ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&D | Sale 10b5-1 | −4,387 | $11.52 | $51K | 84,455 |
| 2024-09-09 | REED ELIZABETH E SVP, GC & CORPORATE SECRETARY | Sale 10b5-1 | −4,387 | $11.52 | $51K | 78,633 |
| 2024-09-09 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −21,125 | $11.52 | $243K | 361,975 |
| 2024-09-09 | Inrig Jula CHIEF MEDICAL OFFICER | Sale | −2,191 | $11.52 | $25K | 62,633 |
| 2024-09-09 | Heerma Peter CHIEF COMMERCIAL OFFICER | Sale | −2,191 | $11.52 | $25K | 107,958 |
Page 22 of 51 · 1,020 trades